Nimacimab
CBeyond
Skye Bioscience · Phase 2 · Active, not recruiting · Enrollment 136
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Nimacimab injection | n/r | n/r | n/r | n/r |
| Nimacimab placebo injection | n/r | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab injection 200 mg | n/r | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab placebo injection | n/r | n/r | n/r | n/r |
| Open-label 300 mg Nimacimab injection (study extension) | n/r | n/r | n/r | n/r |
Not shown
- Nimacimab injection: endpoint not reported
- Nimacimab placebo injection: endpoint not reported
- Semaglutide injection + Nimacimab injection 200 mg: endpoint not reported
- Semaglutide injection + Nimacimab placebo injection: endpoint not reported
- Open-label 300 mg Nimacimab injection (study extension): endpoint not reported